Related Experiment Video
Updated: Jun 21, 2025
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
17.6K
Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent
Parul Thakral1, Ishita Barat Sen1, Subha Shankar Das1
1Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India.
Summary
Lead-212 targeted alpha therapy (TAT) shows promise for metastatic neuroendocrine tumors (NETs). Imaging with lead-203 labeled peptides, like Pb-203 VMT-α-NET, accurately predicts treatment feasibility for NET patients.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Targeted alpha therapy (TAT) using lead-212 (Pb-212) is a promising treatment for metastatic neuroendocrine tumors (NETs).
- Lead-203 (Pb-203) serves as a diagnostic surrogate for Pb-212, enabling feasibility assessment for TAT.
- Somatostatin receptor targeting agents are crucial for delivering therapeutic and diagnostic radionuclides to NETs.
Purpose of the Study:
- To evaluate the diagnostic imaging performance of a novel Pb-203 labeled somatostatin receptor targeting agent, Pb-203 VMT-α-NET.
- To assess the feasibility of subsequent lead-212 targeted alpha therapy (TAT) in a patient with metastatic neuroendocrine tumors (NETs).
- To demonstrate the concordance between Pb-203 VMT-α-NET imaging and standard Gallium-68 DOTANOC imaging in NET patients.
Main Methods:
- A patient with metastatic neuroendocrine tumors (NETs) underwent diagnostic imaging using Pb-203 VMT-α-NET.
- The distribution of Pb-203 VMT-α-NET was compared with imaging data obtained using Ga-68 DOTANOC.
- Analysis focused on the matching uptake patterns between the diagnostic surrogate (Pb-203) and the established imaging agent (Ga-68).
Main Results:
- Imaging with Pb-203 VMT-α-NET successfully visualized the somatostatin receptor-positive metastatic neuroendocrine tumor (NET) lesions.
- The biodistribution of Pb-203 VMT-α-NET demonstrated a matching pattern with that of Ga-68 DOTANOC.
- This concordance suggests that Pb-203 VMT-α-NET can accurately identify suitable candidates for Pb-212 TAT.
Conclusions:
- Pb-203 VMT-α-NET imaging is a valuable tool for assessing the feasibility of Pb-212 targeted alpha therapy (TAT) in metastatic neuroendocrine tumors (NETs).
- The matching distribution with Ga-68 DOTANOC validates its potential as a diagnostic surrogate for Pb-212 TAT.
- This approach supports personalized treatment strategies for NET patients, optimizing the application of advanced radiotherapies.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
105
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
105
01:29Positron Emission Tomography
4.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.1K